QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

$6.20
+0.08 (+1.31%)
(As of 11:28 AM ET)
Today's Range
$5.97
$6.21
50-Day Range
$5.24
$6.34
52-Week Range
$1.26
$6.46
Volume
881,776 shs
Average Volume
1.47 million shs
Market Capitalization
$1.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.31

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
21.9% Upside
$7.31 Price Target
Short Interest
Healthy
1.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Amneal Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.00%
From $0.50 to $0.56 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.73 out of 5 stars

Medical Sector

607th out of 939 stocks

Pharmaceutical Preparations Industry

282nd out of 434 stocks

AMRX stock logo

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

AMRX Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Top 3 Pharma Innovators to Watch Closely
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Amneal Pharmaceuticals (AMRX) Gets a Buy from Barclays
Amneal Pharmaceuticals: Q4 Earnings Insights
Amneal Pharmaceuticals Up 20% In Pre-market - Update
Here's what to expect from Amneal Pharmaceuticals A's earnings report
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2024
Today
3/27/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
Employees
7,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.31
High Stock Price Target
$8.00
Low Stock Price Target
$6.25
Potential Upside/Downside
+19.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-83,990,000.00
Pretax Margin
-1.68%

Debt

Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$1.40 per share
Book Value
$0.07 per share

Miscellaneous

Free Float
224,791,000
Market Cap
$1.88 billion
Optionable
Optionable
Beta
1.32
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price target for 2024?

4 brokers have issued 1-year target prices for Amneal Pharmaceuticals' shares. Their AMRX share price targets range from $6.25 to $8.00. On average, they anticipate the company's stock price to reach $7.31 in the next year. This suggests a possible upside of 21.9% from the stock's current price.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2024?

Amneal Pharmaceuticals' stock was trading at $6.07 on January 1st, 2024. Since then, AMRX stock has decreased by 1.2% and is now trading at $6.00.
View the best growth stocks for 2024 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,070,000 shares, an increase of 13.1% from the February 29th total of 1,830,000 shares. Based on an average daily trading volume, of 1,460,000 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.9% of the company's stock are short sold.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our AMRX earnings forecast
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced its earnings results on Friday, March, 1st. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.07. The business earned $616.98 million during the quarter, compared to the consensus estimate of $630.67 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 126.04% and a negative net margin of 3.51%.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, March, 1st. The company provided earnings per share (EPS) guidance of 0.530-0.630 for the period, compared to the consensus earnings per share estimate of 0.600. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.6 billion.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.45%), Vanguard Group Inc. (4.45%), Rubric Capital Management LP (2.61%), Dimensional Fund Advisors LP (0.92%), Nantahala Capital Management LLC (0.76%) and Nuveen Asset Management LLC (0.64%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners